CA-125:CA72-4 ratio − towards a promising cost-effective tool in ovarian cancer diagnosis and monitoring of post-menopausal women under hormone treatment

Table 1 Diagnostic accuracy for differential diagnosis between benign ovarian diseases and ovarian cancer of CA-125, HE4, ROMA, ROMI algorithm in pre- and post-menopausal women^#

Biomarkers	Cut off Optimal/Preferred	Sensitivity (%) Optimal/Preferred	Specificity (%) Optimal/Preferred	PPV (%) Optimal/Preferred	NPV (%) Optimal/Preferred
Pre-menopausal CA-125	64.6/35 (U/mL)	87.0/86.6	84.1/70.9	44.8/33.6	94.8/96.1
HE4	70.3/140 (pmol/L)	83.5/68.2	89.9/98.6	46.2/86.4	96.7/94.4
ROMA	14.9/11.4%	86.8/86.2	89.1/88.8	42.1/39.6	97.2/98.7
ROMI	53,54%	84.6	93.9	92.8	86.8
Post-menopausal CA-125	39.4/35 (U/mL)	84.1/91.9	96.7/89.8	91.7/83.2	92.8/94.4
HE4	109.1/140 (pmol/L)	83.8/87.1	96.9/94.2	86.8/92.8	89.6/86.2
ROMA	33.4/29.9%	89.0/86.8	95.9/92.2	91.9/89.4	94.2/94.9
ROMI	44.56%	98.2	97.0	99.1	94.1

#This Table provides a synopsis of cut offs, sensitivity, specificity, positive and negative predictive values for all biomarkers and algorithms clinically used in pre- and post-menopausal women for discriminating ovarian cancer from normal conditions
CA-125: carbohydrate antigen or cancer antigen 125, HE4: human epididymis protein 4, ROMA: Risk of Ovarian Malignancy Algorithm, ROMI: Risk of Ovarian Malignancy Index

ISSN: 1757-2215